ArcticZymes Technologies ASA (DE:B4V) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ArcticZymes Technologies ASA has showcased the impressive capabilities of its M-SAN HQ nuclease in enhancing the purification process of recombinant measles viruses, as highlighted in the Journal of Chromatography A. By integrating M-SAN HQ with heparin affinity chromatography, the company has significantly improved both the purity and yield of virus production, offering a more efficient and cost-effective solution for manufacturers. This advancement not only ensures higher product quality but also aids in meeting stringent regulatory standards, accelerating access to safe and effective therapies.
For further insights into DE:B4V stock, check out TipRanks’ Stock Analysis page.